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STUDY QUESTION: How much variation in oocyte yield after controlled ovarian stimulation (COS) can be accounted for by known
patient and treatment characteristics?
SUMMARY ANSWER: There is substantial variation in the COS responses of similar women and in repeated COS episodes undertaken
by the same woman, which cannot be accounted for at present.
WHAT IS ALREADY KNOWN: The goal of individualized COS is to safely collect enough oocytes to maximize the chance of success in
an ART cycle. Personalization of treatment rests on the ability to reduce variation in response through modifiable factors.
STUDY DESIGN, SIZE, DURATION: Multilevel modelling of a routine ART database covering the period 1 October 2008–8 August
2012 was employed to estimate the amount of variation in COS response and the extent to which this could be explained by immutable
patient characteristics and by manipulable treatment variables. A total of 1851 treatment cycles undertaken by 1430 patients were included.
The study was not subject to attrition, as cancelled cycles were included in the analysis.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged 21–43 years undergoing ovarian stimulation for IVF (possibly
with ICSI) using their own eggs at a tertiary care centre.
MAIN RESULTS AND THE ROLE OF CHANCE: Substantial unexplained variation in COS response (oocyte yield): was observed (3.4-
fold (95% CI: 3.12 to 3.61)). Only a relatively small amount of this variation (around 19%) can be explained by modifiable factors. A significant,
previously undescribed predictor of response was the practitioner performing oocyte retrieval, with 1.5-fold variation between surgeons with
the highest and lowest yields.
LIMITATIONS REASONS FOR CAUTION: Although a large number of covariables were adjusted for in the analysis, including those
that were used for dosing and determination of the stimulation regimen, this study is subject to confounding due to unmeasured variables and
measurement error.
WIDER IMPLICATIONS OF THE FINDINGS: The present study suggests that there are limits to the extent that COS response can be
predicted on the basis of known factors, or controlled by manipulation of treatment factors. Moreover, modifiable variation in response appears
to be partially attributable to differences between surgeons performing oocyte retrieval. Consequently, consistent prevention of ineffective or
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unsafe responses to COS is not likely to be possible at present. Our results highlight the importance of blinding surgeons in RCTs. The data also
suggest that there is likely to be limited scope for personalized treatment unless additional predictors of ovarian response can be identified.
STUDY FUNDING/COMPETING INTERESTS: J.W. is funded by a Doctoral Research Fellowship from the National Institute for
Health Research (DRF-2014-07-050) supervised by S.A.R. The views expressed in this publication are those of the authors and not necessar-
ily those of the NHS, the National Institute for Health Research or the Department of Health. J.W. is a statistical editor of the Cochrane
Gynaecology and Fertility Group. S.A.R. is a statistical editor for Human Reproduction. J.W. also declares that publishing peer-reviewed arti-
cles benefits his career. A.L.M. has received consultation fees from MSD, Merck Serono, Ferring, TEVA, Roche, Beckman Coulter.
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Introduction
The goal of controlled ovarian stimulation (COS) in ART is to safely
obtain enough oocytes to maximize the chance of success in the treat-
ment cycle. Frequently, this goal proves elusive; it has been estimated
that 17% of ART stimulation cycles in the UK (Sunkara et al., 2011)
and 28% in the USA (Steward et al., 2014) result in the collection of
over 15 oocytes, representing increased risk to both the woman
(Steward et al., 2014) and any potential offspring (Sunkara et al.,
2015). In total, around 12% of IVF cycles in the UK are cancelled owing
to poor or excessive ovarian response (Kurinczuk, 2010). If this situ-
ation is to be improved, methods to predict and prevent ineffective or
unsafe COS responses are required (La Marca et al., 2012, La Marca
and Sunkara, 2014). To this end, the predictive value of two ovarian
reserve tests (ORT), anti-Mullerian hormone (AMH) and antral follicle
count (AFC), has been demonstrated in relation to COS response
(Broer et al., 2011, 2013). In addition, the dose-responsiveness of
COS response to FSH has also been established (Arce et al., 2014),
although this is likely to be limited to patients with sufficient ovarian
reserve to permit tailoring (Klinkert et al., 2005, Lekamge et al., 2008).
The value of ovarian reserve testing for improving clinical outcomes of
ART is less clear; however, with a recent review of RCTs of
individualized versus standard doses of FSH noting that only one trial in
good prognosis patients had demonstrated an effect on pregnancy
(van Tilborg et al., 2016). The same review concluded that tailoring
the dose of FSH on the basis of ORTs may improve safety, however.
Some support for this is provided by a recent RCT where a multivari-
able dose selection algorithm increased the proportion of participants
obtaining an optimal number of oocytes, albeit using a definition that
was not prespecified (Allegra et al., 2017). A second RCT suggested
that dose-selection using AMH may reduce the overall proportion of
low or excessive responses, although these analyses excluded cycles
cancelled for poor response (which occurred more frequently in the
personalized group) (Nyboe Andersen et al., 2017).
From a statistical perspective, we contend that the challenge of opti-
mizing COS should be viewed as the need to reduce variation in
response. This is somewhat different to the typical situation we face
when designing and testing interventions, where effectiveness is
defined as a shift in an outcome in one direction. In this regard, an
understanding of the sources of variation contributing to the distribu-
tion of COS outcomes would be advantageous (Senn, 2016). In par-
ticular, the amount of unexplained variation represents a limit on our
ability to predict response under a given treatment regimen, and the
degree to which we can manipulate this response depends on the
WHATDOES THIS MEAN FOR PATIENTS?
This paper looks at why women’s bodies respond differently to ovarian stimulation during fertility treatment. The researchers also looked at
how women’s responses change if they are treated more than once. The aim of stimulating the ovaries with drugs during fertility treatment is to
produce a good supply of eggs to maximize the chances of IVF working. Tests known as ovarian reserve tests (such as AMH and antral follicle
count) are often carried out before stimulation begins to see how many eggs the ovaries are likely to produce. This is so that the levels of drugs
given can be individually adjusted to try to make sure the woman does not produce too few or too many eggs. The ideal treatment would result
in all women producing a similar number of eggs, somewhere in between these two extremes.
The researchers looked at women having treatment at one treatment centre who were given different drug regimes depending on the results
of their ovarian test results. They found that differences in the number of eggs obtained were only partially explained by routinely measured
characteristics, such as age and ovarian reserve test results. In addition, differences in how women were treated only explained a very small
amount.
Because these factors do not explain why women respond so differently, it is not possible to reliably predict how a woman will respond to
ovarian stimulation. If two women of similar age with similar ovarian test results are given the same treatment, their responses could be very dif-
ferent. The first woman could get nine eggs, for example, and the second could get as few as four or as many as 19. If the first woman had a
second try, she might produce between 5 and 17 eggs. The researchers also found that the doctor carrying out the egg collection also makes a
difference to how many eggs are collected.
The paper concludes that personalizing ovarian stimulation to the individual woman can currently only be done in a limited way as we still do
not know exactly why women respond differently.
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amount of variation attributable to modifiable factors. This in turn
motivates the identification of additional sources of heterogeneity
which may be incorporated into multivariable prediction and tailoring
algorithms. Moreover, quantifying the degree of variation associated
with known predictors highlights variables to be controlled in clinical
practice and in research. While RCTs should, in principle, produce bal-
ance over nuisance factors between treatment arms, in reality the
impracticability of blinding these trials undermines this in the form of
performance biases (Higgins et al., 2011).
Multilevel modelling is a statistical technique that allows us to attri-
bute variation to known and unknown factors, whilst estimating and
allowing for measured covariate effects. The variation of unknown
source can be apportioned to ‘between-patient’ (factors that are
intrinsic to the patient) and ‘within-patient’ (factors which might vary
between repeated treatment cycles) components (Snijders and
Bosker, 2012). In order to investigate the impact of known and
unknown sources of variation on COS response, we constructed
multilevel models using a large routine ART database. We discuss the
implications for the practice and research of individualized COS.
Materials andMethods
Population
Women aged 21–43 years undergoing ovarian stimulation for IVF (possibly
with ICSI) using their own eggs at the Reproductive Medicine Department
of St Mary’s Hospital, Manchester, UK, from 1 October 2008 to 8 August
2012 were included. Patients that had AMH measured using only the Gen
II assay were excluded, given previously reported problems with this assay
(Rustamov et al., 2012). Patients with ultrasound features of polycystic
ovaries, previous history of salpingectomy, ovarian cystectomy and/or uni-
lateral salpingoophorectomy were excluded from the analysis as we
expected the relationships between patient and treatment characteristics
and response to be distinct in these subgroups. Similarly, small numbers of
cycles with ovarian stimulation other than GnRH agonist long down regula-
tion or short GnRH antagonist cycles were not included in the study.
Severe male factor infertility was defined as the partner having azoo-
spermia, surgical sperm extraction or severe oligospermia, which necessi-
tated using the multiple ejaculation resuspension and centrifugation test for
assisted conception. Mild male factor was defined as abnormal sperm
count that did not meet the aforementioned criteria for severe male infer-
tility. Diagnosis of endometriosis was based on a previous history of endo-
metriosis confirmed using laparoscopy. Diagnosis of endometrioma was
established using a transvaginal ultrasound scan prior to IVF treatment. In
couples without a definite cause for infertility following investigation, the
diagnosis was categorized as unexplained. No patients were pretreated
with oral contraceptive pill, oestrogen or progestins.
Measurement of AMH and AFC
AMH measurements were performed by the Clinical Assay Laboratory of
Central Manchester NHS Foundation Trust, and the procedure for sample
handling and analysis was based on the manufacturer’s recommendations.
Venous blood samples were taken without regard to the day of women’s men-
strual cycle and serum samples were separated within 2 h of venipuncture.
Samples were frozen at −20°C until analysed in batches using the enzymatically
amplified two-site immunoassay (DSL, Active MIS/AMH ELISA; Diagnostic
Systems Laboratories, Webster, TX, USA). The intra-assay coefficient of vari-
ation (CV) (n = 16) was 3.9% (at 10 pmol/l) and 2.9% (at 56 pmol/l). The
inter-assay CV (n = 60) was 4.7% (at 10 pmol/l) and 4.9% (at 56 pmol/l).
Haemolysed samples were not included in the study. In patients with multiple
AMH measurements, the value closest to their IVF treatment cycle was
selected. The working range of the assay was up to 100 pmol/l and the min-
imum detection limit was 0.63 pmol/l. No patients in the present study had
results lower than 0.63 pmol/l. Test results that were higher than the assay
range (two patients) were coded as 150% of the maximum range (150 pmol/l).
In our department, the measurement of AFC is conducted as part of an
initial clinical investigation before the first consultation with clinicians and
prior to the IVF cycle. Qualified radiographers performed the assessment
of AFC during the early follicular phase (Day 0–5) of the menstrual cycle.
Measurement of AFC consisted of the counting of all antral follicles meas-
uring 2–6 mm in longitudinal and transverse cross sections of both ovaries
using a transvaginal ultrasound scan. The AFC measurement closest to the
date of the IVF cycle was selected for the analysis.
Description of COS protocols
On the basis of their AMH measurement, patients were stratified into the
treatment bands for ovarian stimulation using COS protocols. During the
study, two different COS protocols were used and in addition three minor
modifications were made in the second protocol. Time periods, AMH
bands, down regulation regimes, initial dose of gonadotrophins and adjust-
ment of daily dose of gonadotrophins for each protocol are described in
Supplementary Table SI. Similarly, the management of excessive ovarian
response was tailored to pretreatment AMH measurements, although
mainly based on the results of oestradiol and scan monitoring during the
stimulation period (Supplementary Table SI). Assessment of transvaginal
ultrasound guided follicle tracking and serum oestradiol levels on specific
days of the stimulation were used for monitoring of COS (Supplementary
Table SII). The criteria for the cycle cancellation for poor ovarian response
were consistent across all protocols; fewer than 3 follicles >15mm in size
on Day 10 of ovarian stimulation.
Pituitary desensitization regimes
Selection of pituitary desensitization regime was based on the patient’s AMH
according to the COH protocol at the time of commencement of the IVF cycle
(Supplementary Table SI). Long agonist regimes involved daily s.c. injection of
250 μg or 500 μg of the GnRH agonist Buserelin acetate (Supercur, Sanofi
Aventis Ltd., Surrey, UK) from the mid-luteal phase (Day 21) of the preceding
menstrual cycle, which continued throughout ovarian stimulation. Women
treated with antagonist regime had daily s.c. administration of GnRH antagonist
Ganirelex (Orgalutran, Organon Laboratories Ltd., Cambridge, UK) from Day
4 post-stimulation until the day of HCG trigger. Ovarian stimulation was
achieved by injection of a daily dose of hMG, Menopur (Ferring
Pharmaceuticals, UK) or recombinant FSH (rFSH), Gonal F (Merck Serono,
Germany) as per the AMH-tailored protocols (Supplementary Table SI).
Oocyte maturation was triggered using 5000 IU HCG (Pregnyl, Organon
Laboratories Ltd., Cambridge, UK) and the criteria for timing of HCG injection
was consistent across all protocols: one (or more) leading follicles measuring
>18mm and two (or more) follicles>17mm.
Oocyte collection
Oocyte collection was conducted 34–36 h following injection of HCG for
follicle maturation. An ultrasound guided oocyte pick up (OPU) was con-
ducted by experienced clinicians under sedation. Practitioners with a small
number (<10) of oocyte collection procedures were pooled in the analysis
(group J). If the cycle was cancelled before oocyte recovery, it was categor-
ized under the practitioner who was on-call for oocyte recovery on the
day of cycle cancellation.
Oocytes were counted immediately post-OPU by an embryologist. In
patients undergoing ICSI, the assessment of the quality of oocytes was
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conducted 4–6 h post-OPU. Oocytes assessed as in metaphase II stage
(MII) of maturation were categorized as mature.
Study outcomes
We evaluated that the outcomes number of oocytes recovered (IVF and
ICSI cycles) and number of MII oocytes (ICSI cycles only). However, our
estimates relating to MII oocytes were so imprecise as to be quite unin-
formative. Consequently, we present these without further comment.
Statistical analysis
We used multilevel multivariable Poisson regression to estimate the effects
of patient and treatment characteristics on stimulation response (Snijders
and Bosker, 2012). The variables included in the regression models were
selected on the basis of background knowledge and the objectives of the
study. We distinguished patient characteristics (age, AMH, AFC, BMI,
attempt number and cause of infertility) which cannot be altered from
treatment variables (initial dose of gonadotrophin, stimulation regime
(antagonist or long agonist), protocol (old version (v) or v1, v2 and v3 or
v4 of the new protocol), type of gonadotrophin (HMG or rFSH) and OPU
practitioner, which could in principle be used to tailor treatment. The
representation of age, AMH and AFC in the model was determined on the
basis of exploratory analysis consisting of graphing each variable against egg
count and log(egg count), and by comparing models featuring competing
representations using Akaike’s Information Criterion (Akaike, 1972), a
measure of fit that penalizes complexity. As a result of this process, age
was represented as a quadratic in the final analysis, AMH was log-
transformed and AFC was categorized into three levels on the basis of
quantiles. Initial dose of gonadotrophin was represented as a categorical
variable; this decision was made on the basis of the distribution of the
doses and the desire to obtain an easily interpretable model (Table I).
Interactions between regime and other variables, and dose and other vari-
ables were considered using likelihood ratio testing and graphing of the
predictors against egg count within regime and dose categories. Dose
effect was allowed to vary with regime in the final analysis, owing to the
observed significance of this interaction using a likelihood ratio test and the
inherent plausibility of this relationship. We also fitted a version of the final
model with an interaction between log(AMH) and dose, to investigate
whether the relationship between dose and oocyte yield varied with AMH
level. Continuous variables were mean-centred and standardized by divid-
ing by a SD. This was done for the purposes of interpretability and to
improve computational efficiency in model fitting.
Poisson regression models for oocyte yield and number of mature (MII)
oocytes (for ICSI cycles only) as outcome variables were fitted for the final
analysis with multiplicative random effects at both the observation and
patient-levels included to account for the high variability in cycle outcomes
and the correlation between repeated cycles undertaken by the same
patient, respectively. This method produces covariate-adjusted yield ratios
and 95% CIs. For categorical variables, these can be interpreted as relative
yields per cycle for each level of the predictor compared to a reference
category. For continuous variables, they can be interpreted as the multi-
plicative change in the yield per cycle associated with a SD increase in the
predictor. For example, a yield ratio of two would correspond to an
expected doubling of the number of oocytes obtained. We used multiple
imputation to handle the relatively low proportion of missing values in the
dataset (see Table I), including imputed egg counts for cancelled cycles. All
of the variables included in the analysis were used in the imputation pro-
cess, in addition to variables relating to follicle counts on Days 8 and 10 of
the stimulation phase and the total dose of gonadotrophins administered.
........................................................................................
Table I Summary of cycle characteristics in the
dataset.
Characteristic Summary




Initial dose of gonadotrophins (IU) 0%
75–150 IU 297 (16)
187–250 IU 484 (26)
300 IU 919 (50)
375 IU 62 (3)
450 IU 89 (5)

































The dataset contained 1851 treatment cycles (defined as initiation of COS) on
1430 patients. Median, Inter-quartile range and range for continuous variables, fre-
quency and percentage for categorical variables. %missing shown in italics.
AMH, anti-Mullerian hormone; AFC, antral follicle count; rFSH, recombinant FSH.
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We examined plots of residuals and of predictions arising from the analysis
to assess model fit. Analysis was conducted using the software packages R
(R Core Team, 2014, Austria) and RStan (Stan Development Team, 2014,
USA). Imputation was conducted using the mi package (Su et al., 2011).
No sample size calculation was performed, as we were not interested in
hypothesis testing. Instead, we rely on 95% CIs to indicate the precision of
our results. We estimated the amount of unexplained between and
within-patient variation, and of total variation, in three models of oocyte
yield: no covariates; patient covariates only; and treatment and patient
covariates. The first of these models quantifies the variance in the data. By
comparing Models 1—2, we can estimate the amount of variation attribut-
able to patient characteristics and by comparing Models 2–3 we estimate
the amount that could, in principle, be reduced through treatment. We
used the distribution of the random effects from the fitted models to calcu-
late these measures of unexplained variation. Each model yields two ran-
dom effects for each patient in the analysis, which describe how each
patient’s responses differ relative to the outcome that would be expected
according to the model variables (patient and cycle-specific yield ratios).
We calculated the yield ratio for a random effect one SD above the mean
(YRSD), the ratio of the 95th to the 5th random effects (YR90), and the
variance of the random effects for each model, overall and partitioned as
within and between patients. YR90 represents the relative difference
between high and low responses, after controlling for the model covari-
ates. For example, a between-patient YR90 of two would indicate that, if
we had two patients with the same values of the model covariates, we
could reasonably expect the response of one to be double that of the
other.
Results
Characteristics of the sample
The dataset contained 1851 treatment cycles (defined as initiation of
COS) on 1430 patients. A total of 1070 (75%) patients had one cycle,
306 (21%) had two, 56 (4%) had three and one (0%) had four. Six
cycles were cancelled for hyperstimulation, 86 were freeze-all cycles,
and 20 were cancelled for poor response. For ICSI, 1236 cycles on
964 patients were available for the analysis of mature oocytes. Table I
gives a summary of the characteristics of the cycles in the dataset.
Howmuch variation in COS response
is explained by immutable patient
characteristics?
Table II shows measures of unexplained variation (YRSD, YR90, and the
residual variance, see ‘Statistical Analysis’ section) in three models of
COS response.
The reduction in these measures between Models 1 and 2 tells us
how much is explained by patient characteristics. It is evident that
patient characteristics explain a substantial portion of the overall vari-
ation; the total unexplained variance (the sum of the between and
within-patient components) reduces from 0.30 to 0.16 (i.e. to 53% of
the original value) when these are added. This translates to a YRSD of
1.75 in Model 1 compared to 1.51 in Model 2. The YR90 is 6.30 in
Model 1 and 3.87 in Model 2. We can see that known patient charac-
teristics explain variation through the between-patient rather than the
within-patient component (as there is no substantive reduction in the
latter, Table II). This is unsurprising, since these variables tend not to
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Howmuch variation in COS response can be
explained by manipulable treatment factors?
Similarly, a comparison between Models 2 and 3 shows how much
variation can be accounted for by treatment (Table II). Adding treat-
ment variables to the model does reduce overall variation further, but
only modestly. Total variance reduces from 0.16 to 0.13 (81% of the
original). The YRSD are 1.51 and 1.45 in the Models 2 and 3, respect-
ively, and the YR90 are 3.87 and 3.36. As such, the model implies that
there is a limit to the extent to which variation in response can be
reduced by tailoring treatment, with the YR90 of 3.4 implying that a
greater than three-fold difference in yield could reasonably be
observed between two cycles in which two patients with similar char-
acteristics are treated in the same way. If the same patient were to be
treated in the same way on two occasions, a 2.7-fold difference in yield
could reasonably be observed (YR90 = 2.7). This can be translated to
a clinically meaningful scale. Suppose that a patient obtained nine eggs
from a cycle. If another patient with similar characteristics were to be
treated in the same way, we would expect their response to be
between six and 13 eggs (based on YRSD), although any response in
the range four to 19 (based on YR2SD) would not be surprising. If the
same initial patient were stimulated in the same way a second time we
would expect a response between seven and 12 eggs, but any
response between five and 17 eggs should be anticipated.
Effects of known patient and treatment
characteristics
Yield ratios with 95% CIs from the fitted models are presented visually in
Figure 1 and in Supplementary Table SIII. The corresponding estimates for
the analysis of MII oocytes are displayed in Supplementary Fig. SI and
Supplementary Table SIII. These refer to the estimated ‘effects’ of the
predictor variables on COS response, as described in Statistical Analysis
section, above. Notably, the ratio of the greatest to the lowest yield ratio
estimated for the practitioners was 1.53, with differences between opera-
tors apparent on the basis of non-overlapping 95% CIs (Fig. 1). While
AMH was a strong predictor of response, we did not find evidence of dif-
ferential effects of AMH across dose groups (Interaction test: P = 0.60),
although our power to detect such an effect is likely to have been low.
Other predictor variables showed effects in the anticipated directions,
with increased yields for higher AFC values and decreased yields for
increasing age, for example. The model suggested increased yields when
rFSH was used compared to an equivalent starting dose of HMG.
Figure 1 Yield ratios and 95% CIs from the multivariable Poisson regression model of number of oocytes per cycle. Continuous predictors have
been standardized, so that coefficients display the expected multiplicative increase in the yield ratio for a SD change in the variable. Increasing dose
effect under a GnRH antagonist regime is shown by the purple connecting line. Increasing dose effect under a GnRH long agonist regime is shown by
the blue connecting line.
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Discussion
In the present study, we used multilevel modelling of a routine ART
database to quantify the various sources of variation in response to
COS. Our results quantify, and are consistent with, the effects of
known predictors (Fig. 1, Supplementary Table SIII), while large ran-
dom effects (yield ratios) suggest that there remains substantial vari-
ation that we cannot currently account for (a 3.4-fold difference Fig. 1,
Table II). This holds both for differences between the responses of dif-
ferent women and between repeated responses of the same woman.
Only a relatively small amount of this variation (around 19%) can be
explained by modifiable treatment factors.
Patient characteristics
Patient characteristics explained a substantial portion of variation
between women. This included strong relationships with known mea-
sures of ovarian competence (age, AMH, AFC) (La Marca and
Sunkara, 2014). The predictive value of AFC would probably be
improved had it been measured at the start of each cycle, although
our measurement of AFC is in line with other UK centres. A post hoc
sensitivity analysis conducted in first attempts only (removing cycle to
cycle variation) suggested a possible increase in the effect of AFC com-
pared to our main analysis, although this was consistent with chance.
Variation in BMI was quite precisely estimated as having little to no
influence on oocyte yield, possibly because all patients had values in
the range 19–30 kg/m2. It is possible that an adjustment for weight,
rather than BMI, might be more meaningful, however, weight is not
recorded in our database. There was no evidence to suggest that any
particular infertility diagnosis was associated with number of oocytes,
with the exception of increased yields (estimate of 7%, no higher than
14%) for those with unexplained infertility. Number of oocytes
appeared to increase with attempt number, with increased yields for
second attempts and subsequent attempts. This could reasonably be
an artefact caused by selection effects relating to different profiles or
treatment strategies for patients undergoing multiple treatment
attempts, although a sensitivity analysis excluding attempt number had
no discernible impact on the other model estimates or on the amount
of explained variance.
Treatment characteristics
This appears to be the first study to identify a substantial effect of
oocyte recovery practitioner on oocyte yield. It is worth noting that
the operators were all trained, experienced surgeons. While tailoring
of the allocation of patients to practitioner lacks credibility as a treat-
ment protocol, this variability does suggest that there are as yet
unmeasured factors which affect COS outcome, which if identified
may have the potential for optimization. This finding is important, as
variation linked to recovery practitioner could undermine any attempts
to guide a patient to an optimal oocyte yield by tailoring the gonado-
trophin dose. Blinding of the recovery practitioner and recording of
the allocation of patients to practitioner should be a mandatory feature
of RCTs of personalized COS.
In line with previous research in this area (Arce et al., 2014), the
model suggested a dose-response relationship between initial gonado-
trophin dose and number of oocytes at lower doses. However, this
did not appear to be sustained beyond the lowest dose. This suggests
that, to the extent that tailoring the dose is possible, it should be
restricted to a lower dose range (Fig. 1). Differences between antag-
onist and long agonist regimens were generally unclear, other than for
the 75–150 IU dose band where we observed a reduced number of
oocytes in antagonist cycles. In order to translate dose and regimen
effects to a more easily interpretable scale, we plotted the observed
oocyte yields together with the predicted oocyte yields from our mod-
el for patients falling in low, medium and high AMH bands, using cut-
offs of <5, 5–15 and >15 pmol/l, which have been suggested (Nelson
et al., 2007) and used (Nelson et al., 2009) elsewhere in the literature
(Fig. 2). This represents the predicted outcomes for our centre, were
dose selection performed solely on the basis of AMH. Figure 2 high-
lights the impact of other sources of variation that should be con-
sidered in individualized COS, because the variation within each
AMH/protocol/dose category is large relative to the variation
between categories, and suggests that multivariable algorithms
(Popovic-Todorovic et al., 2003, La Marca et al., 2012) will be needed
to obtain reliable predictions of response. However, our models also
suggest that many of these contributory variables remain unknown.
We did not replicate the finding of Arce et al. (2014) that dose effects
vary according to AMH, although our power to detect an effect of this
nature is likely to have been low. The predictions appear to be consist-
ent with existing research and writing on this topic, indicating in par-
ticular that increasing the dose in patients with predicted low response
is unlikely to increase the oocyte yield (Klinkert et al., 2005, Lekamge
et al., 2008) and that dose-effects on the mean response are modest
(Sterrenburg et al., 2011).
In this case, the effect on the mean response may not represent
the most useful measure of efficacy however. Given that the goal of
individualized COS is to prevent insufficient or unsafe responses
(La Marca et al., 2012), we believe that it is most useful to focus on
the effects of interventions on reducing variation in outcome. In this
context, an intervention could be ‘effective’ even if no effect on the
mean was observed. Our analysis suggests that treatment differ-
ences account for relatively little of this variation, and this is likely to
limit the extent to which extreme responses can be prevented by
tailoring treatment. A unidirectional mean effect will of course be
more relevant in populations of expected poor or high responders
compared to unselected patients, although even then a simple
‘mean difference’ may conceal deleterious consequences of treat-
ment (if, for example, more expected high (low) responders end up
having poor (excessive) responses, as appears to be the case in
Nyboe Andersen et al., 2017). As a result, many trials quantify COS
response by categorizing responses as ‘poor’,’normal’ or ‘high’, and
use this as a trial endpoint (eg: Allegra et al., 2017; Popovic-Todorovic
et al., 2003). This is not entirely unreasonable if the criteria are prede-
fined and cancelled cycles are included in the denominator, although
categorizing measurements in this way reduces power in the trial, neces-
sitating larger sample sizes (Altman and Royston, 2006). We note that
simple statistical methods exist for comparing variation between treat-
ment arms directly, such as Levene’s test (Schultz, 1985).
Limitations of the present study should be noted. There may be
concerns over the generalizability of our findings, since some of the
doses administered in the dataset are higher than would typically be
used, for example, throughout Europe. However, we note here that
our concern is not in the evaluation of any particular treatment strat-
egy, but rather to tease apart the contributions of various predictors
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on COS response. Regardless, we conducted a sensitivity analysis
where we fitted a model in the subset of participants treated with
doses of 225 IU or lower (Supplementary Fig. S2). The estimates are
consistent with our main analysis, albeit with reduced precision due to
the reduction in sample size. While we included a large number of pre-
dictor variables, there is likely to be confounding due to unmeasured
predictors as well as ‘residual confounding’ due to measurement error
in the model covariates (Sterne et al., 2016). In particular, there may
be concern around confounding by indication due to selection for
treatment on the basis of prognosis (Walker, 1996). In this regard, we
note that we have included all of the variables that were used for treat-
ment allocation in the model (at least in principle), and measures of
balance between dose groups (McCaffrey et al., 2013) suggest a rea-
sonable degree of balance after adjusting for covariates, other than for
the highest versus the lowest dose band. In addition, there are plaus-
ible sources of variation which we have not been able to incorporate
into the model. For example, rFSH was initiated between Days 2 and
4 in GnRH antagonist cycles, and the exact start day might explain
some of the variation. Another example would be the length of the
menstrual cycle. We note that the predictive value would have to be
large to substantively change our conclusions regarding the scope for
individualized treatment. Nonetheless, it remains to quantify these
possible sources of variation. Total dose and stimulation duration
were not included in the model. This is because these factors are
Figure 2 Distribution of observed egg counts. Distribution of observed egg counts (box and whisker plots) with those predicted under the model
for low (DSL assay <5 pmol/l), medium (5–15 pmol/l) and high (>15 pmol/l) anti-Mullerian hormone (AMH) bands for both GnRH long agonist
(blue) and GnRH antagonist (purple) regimes. Solid line represents the mean response from the posterior predictive distribution. Shaded area repre-
sents ±1 SD. Note that other covariate values are not fixed but reflect the characteristics of the sample. Only groups with five or more observations
are shown.










ercio user on 28 February 2020
largely determined by the patient response, as observed on ultra-
sound. Total dose is effectively a surrogate outcome for anticipated
stimulation response; dose is increased when things are going poorly.
When we include total dose as a covariate, for example, the estimate
is negative (Supplementary Table SIV). It would, therefore, constitute
a statistical error to include these variables in the model, as to do so
would be to adjust for some of the response. We have instead
included the pre-treatment variable ‘protocol’, which captures policy
changes in relation to stimulation. This will, of course, be subject to
measurement error arising from variation in protocol adherence.
Although, we present a sensitivity analysis including total dose and
stimulation duration in Supplementary Table SIV, we would stress that
we do not believe that this model is interpretable.
We suggest that an understanding of the degree and determinants
of variation in COS response is key to improving clinical practice and
conducting research in this area.
The goal of personalized COS is to reduce this variation, and this
may be assisted both by incorporating a range of predictive patient
characteristics into dose algorithms and by attempting to standardize
aspects of treatment that may introduce noise (Senn, 2016). Our
results indicate that much of the variation in response cannot be
explained by known factors however. We have identified the oocyte
recovery practitioner as one potential source of variation in this study,
and recommend that blinding is used in RCTs to reduce associated
performance biases. Moreover, we advise that the allocation of partici-
pant to practitioner is recorded and considered as a covariate in any
analysis. We conclude that, until additional predictors of variation are
identified, consistent prevention of extreme responses is unlikely to be
achieved.
Supplementary data
Supplementary data are available at Human Reproduction Open online.
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